# Pharmacological Activation of HMN for OSA

> **NCT03640052** · PHASE1,PHASE2 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 6 (actual)

## Conditions studied

- Obstructive Sleep Apnea

## Interventions

- **DRUG:** Placebo oral capsule
- **DRUG:** LTM1201L
- **DRUG:** LTM1201LN
- **DRUG:** LTM1201LB
- **DRUG:** LTM1201LD

## Key facts

- **NCT ID:** NCT03640052
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-30
- **Primary completion:** 2019-09-30
- **Final completion:** 2019-12-31
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2020-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03640052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03640052, "Pharmacological Activation of HMN for OSA". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03640052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*